Search Results - "Bhavsar, Erica B."

Cancer-Associated SF3B1 Hotspot Mutations Induce Cryptic 3′ Splice Site Selection through Use of a Different Branch Point by Darman, Rachel B., Seiler, Michael, Agrawal, Anant A., Lim, Kian H., Peng, Shouyong, Aird, Daniel, Bailey, Suzanna L., Bhavsar, Erica B., Chan, Betty, Colla, Simona, Corson, Laura, Feala, Jacob, Fekkes, Peter, Ichikawa, Kana, Keaney, Gregg F., Lee, Linda, Kumar, Pavan, Kunii, Kaiko, MacKenzie, Crystal, Matijevic, Mark, Mizui, Yoshiharu, Myint, Khin, Park, Eun Sun, Puyang, Xiaoling, Selvaraj, Anand, Thomas, Michael P., Tsai, Jennifer, Wang, John Y., Warmuth, Markus, Yang, Hui, Zhu, Ping, Garcia-Manero, Guillermo, Furman, Richard R., Yu, Lihua, Smith, Peter G., Buonamici, Silvia

“…Recurrent mutations in the spliceosome are observed in several human cancers, but their functional and therapeutic significance remains elusive. SF3B1, the…”
Get full text

Epigenetic evolution and lineage histories of chronic lymphocytic leukaemia by Gaiti, Federico, Chaligne, Ronan, Gu, Hongcang, Brand, Ryan M., Kothen-Hill, Steven, Schulman, Rafael C., Grigorev, Kirill, Risso, Davide, Kim, Kyu-Tae, Pastore, Alessandro, Huang, Kevin Y., Alonso, Alicia, Sheridan, Caroline, Omans, Nathaniel D., Biederstedt, Evan, Clement, Kendell, Wang, Lili, Felsenfeld, Joshua A., Bhavsar, Erica B., Aryee, Martin J., Allan, John N., Furman, Richard, Gnirke, Andreas, Wu, Catherine J., Meissner, Alexander, Landau, Dan A.

“…Genetic and epigenetic intra-tumoral heterogeneity cooperate to shape the evolutionary course of cancer 1 . Chronic lymphocytic leukaemia (CLL) is a highly…”
Get full text

Idelalisib-associated Colitis: Histologic Findings in 14 Patients by Weidner, Anna-Sophie, Panarelli, Nicole C, Geyer, Julia T, Bhavsar, Erica B, Furman, Richard R, Leonard, John P, Jessurun, Jose, Yantiss, Rhonda K

“…Idelalisib is an inhibitor of the PI3Kδ isoform approved for treatment of patients with relapsed chronic lymphocytic leukemia and indolent non-Hodgkin…”
Get full text

Assessment of the Efficacy of Therapies Following Venetoclax Discontinuation in CLL Reveals BTK Inhibition as an Effective Strategy by Mato, Anthony R, Roeker, Lindsey E, Jacobs, Ryan, Hill, Brian T, Lamanna, Nicole, Brander, Danielle, Shadman, Mazyar, Ujjani, Chaitra S, Yazdy, Maryam Sarraf, Perini, Guilherme Fleury, Pinilla-Ibarz, Javier A, Barrientos, Jacqueline, Skarbnik, Alan P, Torka, Pallawi, Pu, Jeffrey J, Pagel, John M, Gohil, Satyen, Fakhri, Bita, Choi, Michael, Coombs, Catherine C, Rhodes, Joanna, Barr, Paul M, Portell, Craig A, Parry, Helen, Garcia, Christine A, Whitaker, Kate J, Winter, Allison M, Sitlinger, Andrea, Khajavian, Sirin, Grajales-Cruz, Ariel F, Isaac, Krista M, Shah, Pratik, Akhtar, Othman S, Pocock, Rachael, Lam, Kentson, Voorhees, Timothy J, Schuster, Stephen J, Rodgers, Thomas D, Fox, Christopher P, Martinez-Calle, Nicolas, Munir, Talha, Bhavsar, Erica B, Bailey, Neil, Lee, Jason C, Weissbrot, Hanna B, Nabhan, Chadi, Goodfriend, Julie M, King, Amber C, Zelenetz, Andrew D, Dorsey, Colleen, Bigelow, Kayla, Cheson, Bruce D, Allan, John N, Eyre, Toby A

“…Venetoclax-based therapy is a standard-of-care option in first-line and relapsed/refractory chronic lymphocytic leukemia (CLL). Patient management following…”
Get full text

A retrospective comparison of venetoclax alone or in combination with an anti-CD20 monoclonal antibody in R/R CLL by Mato, Anthony R., Roeker, Lindsey E., Eyre, Toby A., Nabhan, Chadi, Lamanna, Nicole, Hill, Brian T., Brander, Danielle M., Barr, Paul M., Lansigan, Frederick, Cheson, Bruce D., Singavi, Arun K., Yazdy, Maryam Sarraf, Shah, Nirav N., Allan, John N., Bhavsar, Erica B., Rhodes, Joanna, Kennard, Kaitlin, Schuster, Stephen J., Williams, AnnaLynn M., Skarbnik, Alan P., Goy, Andre H., Goodfriend, Julie M., Dorsey, Colleen, Coombs, Catherine C., Tuncer, Hande, Ujjani, Chaitra S., Jacobs, Ryan, Winter, Allison M., Pagel, John M., Bailey, Neil, Schuh, Anna, Shadman, Mazyar, Sitlinger, Andrea, Weissbrot, Hanna, Muralikrishnan, Sivraj, Zelenetz, Andrew, Kirkwood, Amy A., Fox, Christopher P.

“…Venetoclax (VEN) is approved for relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL) as monotherapy (VENmono) or in combination with rituximab…”
Get full text

At-risk patient and healthcare provider perspectives on clinical trial participation for ductal carcinoma in situ by Adams, Elizabeth, Kulkarni, Swati, Zheng, Veronica, Warwar, Samantha Ahsan, Brown, Denisha, Schulte, Lauren, Cooper, Robin, Labomascus, Bazil, Bhavsar, Erica B.

“…10539 Background: Significant challenges exist in recruiting newly diagnosed ductal carcinoma in situ (DCIS) patients to participate in presurgical…”
Get full text

Molecular Genetics and Prognosis in Younger Patients with Chronic Lymphocytic Leukemia (CLL) by Helbig, Daniel, Abu Zeinah, Ghaith, Bhavsar, Erica B, Furman, Richard R., Allan, John N.

“…Background: While CLL is commonly diagnosed in older patients, there are ~15% of patients diagnosed at ages younger than 50. Several past studies have…”
Get full text

Outcomes in chronic lymphocytic leukemia (CLL) patients with NOTCH1 signaling pathway mutations by Helbig, Daniel R., Abu Zeinah, Ghaith F, Bhavsar, Erica B., Allan, John N.

“…Abstract only 7524 Background: NOTCH1 is one of the most frequently mutated genes in CLL and has emerged as a marker of poor prognosis. Additional mutations in…”
Get full text

A Clinical Review of the Co-Occurrence of Myeloproliferative and Lymphoproliferative Neoplasms by Krichevsky, Spencer, Bhavsar, Erica B, Furman, Richard R., Niesvizky, Ruben, Ritchie, Ellen K., Inghirami, Giorgio, Scandura, Joseph

“…The co-occurrence of myeloproliferative (MPN) and lymphoproliferative neoplasms (LPN) is rare and many publications have been limited to small case reports…”
Get full text

CD79b Expression in Richter's Transformation by Allan, John N., Bhavsar, Erica B, Vaisitti, Tiziana, Sarno, Vincent, Liu, Yifang, Arruga, Francesca, Joyce, Maureen, Schulz, Mathias, Deaglio, Silvia, Furman, Richard R., Chadburn, Amy

“…Background The B cell receptor (BCR) is a signaling complex composed of surface immunoglobulin and heterodimer subunits, Igα (CD79a) and Igβ (CD79b) (Sanchez,…”
Get full text

Single-Cell Multi-Omics Reveals Distinct Paths to Survival of Admixed BTKC481 Mutant Vs. Wild-Type Cells in Clinically Progressing Chronic Lymphocytic Leukemia by Lipsky, Andrew, Luan, Danny, Chen, Shirley, Chaligne, Ronan, Dusaj, Neville, Bhavsar, Erica B, Ang, Chelston, Nam, Anna S, Gaiti, Federico, Chamely, Paulina, Omans, Nathaniel D., Trisal, Preeti, Gandhi, Anita K, Kim, Kyu-Tae, Schulman, Rafael, Schiffman, Joshua S., Izzo, Franco, Mullokandov, Gregory, Underbayev, Chingiz, Wiestner, Adrian, Allan, John N., Furman, Richard R., Landau, Dan A.

“…Mutations in the kinase binding domain of BTK at position C481 are associated with resistance to BTK inhibitor (BTKi) therapy in chronic lymphocytic leukemia…”
Get full text

FAT1 Mutations Influence Time to First Treatment in Untreated CLL by Jakubowski, Chris D., Felsenfeld, Joshua, Bhavsar, Erica B., Holjencin, Jacquelyn R., Thomas, Emilee A., Furman, Richard R, Allan, John N.

“…Introduction: Despite mapping of the mutational landscape in patients (pts) with chronic lymphocytic leukemia (CLL), there remains limited information…”
Get full text

Understanding the Differences between Clinical Trial Participants and Real-World Patients with Non-Hodgkin Lymphoma by Fatola, Tolulope, Rutherford, Sarah C., Allan, John N., Ruan, Jia, Furman, Richard R., Zhengming, Chen, Garcia, Arcania, Kong, Channy, Bhavsar, Erica B, Falsenfeld, Joshua, Leonard, John P., Martin, Peter

“…Introduction. Recent research in lymphoma has resulted in better outcomes for clinical trial populations. Population studies have suggested that some…”
Get full text

Targeting Cellular Metabolism and Survival in Chronic Lymphocytic Leukemia and Richter Syndrome Cells By a Novel NF-Kb Inhibitor by Vaisitti, Tiziana, Gaudino, Federica, Ouk, Samedy, Serra, Sara, Zakrzewski, Johannes L., Bhavsar, Erica B., Allan, John N., Liou, Hsiou-Chi, Furman, Richard R., Deaglio, Silvia

“…BACKGROUND: Tumor cell survival critically depends on heterotypic communications with non-malignant cells in the microenvironment. Most of these signals…”
Get full text

Adenosine Signaling Mediates Hypoxic Responses in the Chronic Lymphocytic Leukemia Microenvironment by Serra, Sara, Brusa, Davide, Vaisitti, Tiziana, Buonincontri, Roberta, Audrito, Valentina, Coscia, Marta, Rossi, Davide, Bhavsar, Erica B., Furman, Richard R., Gaidano, Gianluca, Deaglio, Silvia

“…Extracellular adenosine generated from ATP/ADP through the concerted action of the ectoenzymes CD39 and CD73 elicits potent cytoprotective and…”
Get full text

Efficacy of Therapies Following Venetoclax Discontinuation in CLL: Focus on B-Cell Receptor Signal Transduction Inhibitors and Cellular Therapies by Mato, Anthony R., Roeker, Lindsey E., Eyre, Toby A., Jacobs, Ryan, Hill, Brian T., Lamanna, Nicole, Brander, Danielle M., Shadman, Mazyar, Ujjani, Chaitra, Yazdy, Maryam, Perini, Guilherme Fleury, Pinilla Ibarz, Javier, Barrientos, Jacqueline C, Skarbnik, Alan, Torka, Pallawi, Pu, Jeffrey J, Pagel, John M., Gohil, Satyen, Fakhri, Bita, Choi, Michael Y., Coombs, Catherine C., Rhodes, Joanna, Barr, Paul M., Portell, Craig A., Parry, Helen, Garcia, Christine Ann, Whitaker, Kate J, Winter, Allison M., Sitlinger, Andrea, Khajavian, Sirin, Grajales-Cruz, Ariel F, Isaac, Krista, Shah, Pratik, Akhtar, Othman S., Pocock, Rachael, Lam, Kentson, Voorhees, Timothy J, Schuster, Stephen J., Rodgers, Thomas David, Martinez-Calle, Nicolas, Munir, Talha, Bhavsar, Erica B, Bailey, Neil, Lee, Jason C., Weissbrot, Hanna, Nabhan, Chadi, Goodfriend, Julie, King, Amber C., Zelenetz, Andrew D., Dorsey, Colleen, Bigelow, Kayla, Cheson, Bruce D., Fox, Christopher P, Allan, John N.

“…Introduction: Venetoclax (VEN) based therapy has become a standard of care in front line and relapsed-refractory (R/R) CLL based on favorable efficacy and…”
Get full text

Venetoclax As Monotherapy or in Combination: Patterns of Use and Predictors of Outcomes in an International Multicenter Study of CLL Patients by Mato, Anthony R., Roeker, Lindsey E., Eyre, Toby A., Nabhan, Chadi, Lamanna, Nicole, Hill, Brian T., Brander, Danielle M., Barr, Paul, Lansigan, Frederick, Cheson, Bruce, Singavi, Arun K, Yazdy, Maryam, Shah, Nirav N, Allan, John N., Bhavsar, Erica B, Rhodes, Joanna, Kennard, Kaitlin, Schuster, Stephen J., Williams, Annalynn M, Skarbnik, Alan P, Goy, Andre, Coombs, Catherine C., Tuncer, Hande H., Ujjani, Chaitra S., Jacobs, Ryan, Winter, Allison M., Pagel, John M., Bailey, Neil, Schuh, Anna, Shadman, Mazyar, Sitlinger, Andrea, Weissbrot, Hanna, Muralikrishnan, Sivraj, Kirkwood, Amy A, Fox, Christopher P.

“…Introduction: Venetoclax (Ven) is approved for relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL) as monotherapy (Ven mono) or in combination (Ven…”
Get full text

SLAMF1/CD150 Activates Autophagy in Chronic Lymphocytic Leukemia Cells, Modulating Chemotaxis and Responses to Therapy by Bologna, Cinzia, Buonincontri, Roberta, Serra, Sara, Vaisitti, Tiziana, Audrito, Valentina, Brusa, Davide, Pagnani, Andrea, Coscia, Marta, D'Arena, Giovanni, Bhavsar, Erica B., Furman, Richard R., Rossi, Davide, Gaidano, Gianluca, Terhorst, Cox, Deaglio, Silvia

“…Human SLAMF1 (signaling-lymphocytic-activation-molecule-family1, CD150) is a self-ligand adhesion/co-stimulatory molecule wich belongs to a family of 9…”
Get full text

Heterozygous Hotspot SF3B1 Mutations Found in Myelodysplastic Syndromes Downregulate Genes Involved in Differentiation of Erythroid Cells by Buonamici, Silvia, Darman, Rachel, Perino, Samantha, Agrawal, Anant, Peng, Shouyong, Seiler, Michael, Lim, Kian Huat, Bhavsar, Erica B., Feala, Jacob, Obeng, Esther A., Bailey, Suzanna, Chan, Betty, Fekkes, Peter, Keaney, Gregg F., Kumar, Pavan, Kunii, Kaiko, Lee, Linda, Mackenzie, Crystal, Matijevic, Mark, Mizui, Yoshiharu, Myint, Khin, Park, Eunice, Pazolli, Ermira, Thomas, Michael, Wang, John, Warmuth, Markus, Yu, Lihua, Zhu, Ping, Furman, Richard R., Ebert, Benjamin L, Smith, Peter G

“…Heterozygous mutations in several core members of the spliceosome complex have been reported in Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia…”
Get full text